Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
About Kronos Bio, Inc.
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription. Transcriptional dysregulation is a hallmark of many complex diseases, and Kronos Bio employs its proprietary discovery engine to decode transcription factor regulatory networks, identifying druggable cofactors that play critical roles in disease progression. By targeting these cofactors in a disease-specific context, the company aims to transform patient outcomes in areas of significant unmet medical need.
Proprietary Technology and Expertise
Kronos Bio's competitive edge lies in its proprietary discovery platform, which integrates high-throughput screening strategies and small molecule microarray (SMM) technology. This platform enables the company to identify and optimize small molecules that specifically target transcriptional drivers of disease. The focus on transcription factor regulatory networks allows Kronos Bio to address historically recalcitrant targets, opening new therapeutic possibilities in oncology and autoimmune diseases.
Pipeline and Therapeutic Focus
The company's pipeline includes multiple drug candidates at various stages of development:
- Istisociclib (KB-0742): A CDK9 inhibitor designed to address MYC deregulation in solid tumors, currently being evaluated in a Phase 1/2 clinical trial for platinum-resistant high-grade serous ovarian cancer.
- KB-9558: A p300 lysine acetyltransferase (KAT) inhibitor targeting IRF4 dependence in multiple myeloma and HPV-driven tumors, with preclinical data demonstrating potential tumor suppression through restoration of p53 and Rb pathways.
- KB-7898: Kronos Bio's first autoimmune development candidate, targeting Sjögren’s disease. This p300 KAT inhibitor modulates inflammatory signaling pathways and has shown preclinical efficacy in reducing inflammatory cytokines and antibody production.
By focusing on these disease-specific mechanisms, Kronos Bio aims to provide therapeutic solutions for patient populations with limited or no treatment options.
Market Position and Challenges
Operating within the highly competitive biopharmaceutical industry, Kronos Bio faces challenges such as the inherent risks of drug development, regulatory hurdles, and the need for substantial financial resources. However, its emphasis on transcriptional dysregulation as a therapeutic target sets it apart from competitors, offering a unique value proposition. The company's focus on oncology and autoimmune diseases—markets with high unmet medical needs—positions it as a key player in these segments.
Commitment to Innovation
Kronos Bio's mission is underpinned by a commitment to scientific excellence and innovation. By leveraging its advanced discovery engine and expertise in transcriptional biology, the company continues to push the boundaries of what is possible in drug discovery and development. Its efforts are directed toward creating first-in-class therapies that have the potential to significantly improve the lives of patients worldwide.
Kronos Bio, Inc. (Nasdaq: KRON) has reported progress in its clinical programs, including the Phase 3 AGILITY trial for entospletinib targeting NPM1-mutated acute myeloid leukemia (AML). The company has $292.4 million in cash, expected to fund operations into Q4 2024. R&D expenses were $22.7 million with a net loss of $32.9 million, or $0.59 per share, for Q2 2022. Preclinical data presented at EHA congress supports the development of SYK inhibitors in genetically defined AML subsets. The company is also advancing its CDK9 inhibitor, KB-0742, and plans to announce a recommended Phase 2 dose soon.
Kronos Bio presented promising preclinical data on its SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association (EHA) 2022 Congress. These findings bolster support for targeting spleen tyrosine kinase (SYK) in genetically defined acute myeloid leukemia (AML) subsets. The Phase 3 AGILITY trial of entospletinib is exploring its efficacy alongside chemotherapy in NPM1-mutated AML, with data expected in late 2023. The research indicates potential anti-tumor activity and improved T-cell responses, highlighting a novel therapeutic mechanism.
Kronos Bio, Inc. (Nasdaq: KRON) will have President and CEO Norbert Bischofberger participate in investor conferences. Bischofberger will appear at the Jefferies Healthcare Conference on June 8, 2022, at 4:30 p.m. ET, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 3:20 p.m. PT. Live webcasts will be accessible on the Kronos Bio website, with replays available for 30 days post-event. Kronos Bio focuses on therapies for cancer treatment, notably developing entospletinib for NPM1-mutated AML and KB-0742 for MYC-amplified tumors.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the H.C. Wainwright Global Investment Conference, with a webcast presentation scheduled for May 24, 2022, at 7 a.m. ET. This on-demand presentation will be accessible through their website, allowing investors to catch up after the event as a replay will be available for 30 days.
The company focuses on developing therapies for cancer, particularly through their investigational treatment, entospletinib, targeting NPM1-mutated acute myeloid leukemia.
Kronos Bio, Inc. (Nasdaq: KRON) announced the presentation of preclinical data on its investigational SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association 2022 Congress. The Phase 3 AGILITY study of entospletinib in NPM1-mutated acute myeloid leukemia (AML) is underway, with results expected in late 2023. Lanraplenib is being tested in a Phase 1b/2 study for relapsed/refractory AML. Key findings indicate strong predictive markers for entospletinib's efficacy and synergistic effects with other targeted therapies. The company aims to advance its pipeline amid challenging market conditions.
Kronos Bio, Inc. (Nasdaq: KRON) announced its first quarter 2022 financial results and business updates, reporting a net loss of $36.3 million or $0.65 per share. The company has $315.4 million in cash and investments, ensuring a financial runway into the second half of 2024. Progress was made on three clinical programs, including the CDK9 inhibitor KB-0742, with preclinical data presented at AACR supporting its efficacy in various cancers. The company also opened additional sites for the SYK inhibitor clinical trial and plans to announce further data in Q4 2022.
Kronos Bio has showcased preclinical data on KB-0742, a selective CDK9 inhibitor, at the AACR Annual Meeting 2022. The data suggest its potential efficacy against triple-negative breast, ovarian, and small-cell lung cancers, as well as lymphoma and other rare tumors. The company is advancing its Phase 1/2 clinical trial, which began enrolling patients in February 2021, with additional results expected in Q4 2022. A new liquid biopsy assay is also being presented to evaluate patient responses. These findings support future development stages for KB-0742.
Kronos Bio (Nasdaq: KRON) is set to present preclinical data on its CDK9 inhibitor, KB-0742, at the AACR Annual Meeting 2022. This includes findings from studies on MYC-amplified cancers such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. The ongoing Phase 1/2 trial has yielded preliminary positive data, with the company expected to announce the recommended Phase 2 dose by Q4 2022. Additionally, the research features a liquid biopsy assay to monitor patient responses. The poster presentations will take place on April 12 and April 10, 2022, in New Orleans.
Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer therapies, will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. CEO Norbert Bischofberger, Ph.D., is scheduled to join the "Novel Oncology Targets" panel on March 7 at 12:50 p.m. ET. A live webcast of the discussion will be available on the company's website, with a replay archived for 30 days. Kronos is developing treatments targeting dysregulated transcription in cancer, including its lead compound, entospletinib, for NPM1-mutated acute myeloid leukemia.
Kronos Bio reported progress in its clinical pipeline and financial results for Q4 and full-year 2021. The company continues to enroll patients in the Phase 1/2 trial of the CDK9 inhibitor KB-0742, expecting to announce a recommended Phase 2 dose and updated data in Q4 2022. The Phase 3 AGILITY trial of entospletinib is underway, aiming for results in H2 2023. As of December 31, 2021, Kronos had $339.5 million in cash, expected to fund operations into H2 2024. The company's Q4 net loss was $62.3 million, or $1.13 per share.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
What does Kronos Bio specialize in?
What is Kronos Bio's proprietary discovery engine?
What are Kronos Bio's main therapeutic areas?
What are Kronos Bio's key drug candidates?
How does Kronos Bio differentiate itself from competitors?
What is Istisociclib (KB-0742)?
What is KB-9558 designed to treat?
What is KB-7898's therapeutic focus?
Where is Kronos Bio headquartered?
What challenges does Kronos Bio face?
